[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-associated-diarrhea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-associated-diarrhea":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100610966",false,"NCT07234448","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use: a Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Male and female participants aged 0-12 years.\n* Undergoing antibiotic therapy with amoxicillin or amoxicillin\u002Fclavulanic acid.\n* Parent or legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* Use of antibiotic therapy within 4 weeks prior to enrolment.\n* Use of other probiotic products or lactic acid bacteria during the study.\n* Pre-existing diarrhea within 4 weeks prior to enrolment.\n* Chronic inflammatory bowel disease.\n* Immunodeficiency.\n* Lack of parental or legal guardian consent to participate in the study.","ALL","0 Years","12 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 (Brevicillin® gocce) in preventing gastrointestinal side effects associated with antibiotic therapy using amoxicillin or amoxicillin\u002Fclavulanic acid in pediatric patients aged 0-12 years. Participants will be randomized 1:1 to receive either the probiotic supplement or placebo during standard antibiotic treatment for 6-10 days, followed by a post-treatment observation period up to day 15 without probiotic or placebo administration. The primary objective is to assess the reduction in the incidence of antibiotic-associated diarrhea (AAD).",[26],"Antibiotic-associated Diarrhea","NOT_YET_RECRUITING","2025-11-19",{"date":30,"type":31},"2025-11-24","ACTUAL",{"date":33,"type":20},"2025-12-01",{"date":35,"type":20},"2026-05-29",{"name":37,"class":38},"Liaquat University of Medical & Health Sciences","OTHER",{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100354490","NCT03895593","Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections","Rescue Fecal Microbiota Transplantation for Refractory Intestinal Infections: China National Registry","Inclusion Criteria: National patients with refractory intestinal infections receiving rescue FMT from the China Microbiota Transplantation System from September 2015 to December, 2029 will be included.\n\n\\-\n\nExclusion Criteria: Patients will be excluded from the analysis if they are not followed up for at least 12 weeks post-FMT.\n\n\\-",{"count":46,"type":20},100,"OBSERVATIONAL","A national data registry of patients receiving the rescue fecal microbiota transplantation for the refractory intestinal infections from the China Microbiota Transplantation System was designed to assess the short-term and long-term safety and efficacy.",[50,51,26],"Intestinal Infection","Clostridioides Difficile Infection",[53,54,55,26,56],"fecal microbiota transplantation","intestinal infection","clostridioides Difficile Infection","Washed microbiota transplantation","RECRUITING","2024-02-27",{"date":60,"type":31},"2024-02-29",{"date":62,"type":31},"2015-09-25",{"date":64,"type":20},"2029-05-01",{"name":66,"class":38},"The Second Hospital of Nanjing Medical University",1,""]